Researchers at Novartis BioMedical Research in the US and Switzerland have identified a molecular target that may provide a ...

Because the KRAS protein is difficult to block, Dr. Grisham, Dr. Solit, and their colleagues believe this combination approach is likely to be more effective. Ellen was first diagnosed with stage 3 ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Nutritional counseling remains a central component of obesity treatment, even in the era of highly effective weight-loss ...

PMV Pharma ended the first quarter with $165.8 million in cash, cash equivalents, and marketable securities, compared to $183.3 million as of December 31, 2024. Net cash used in operations was $18.3 ...

Scientists from MD Anderson earlier this week published evidence from mouse models showing that blocking a protein called CREB1 could block mutant KRAS, plus another cancer gene called g53 ...

a protein involved in pancreatic cancer ... Researchers Uncover New Role of Mutant Proteins in Some of the Deadliest Cancers Nov. 11, 2024 — Researchers have discovered a new way in which RAS ...